Ozempic Rx®

Ozempic contains semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA). By mimicking endogenous GLP-1, it enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon, slows gastric emptying, and reduces appetite, collectively improving glycaemic control and promoting weight loss.


Safety profile & boxed warning

| Most common (≥5 %) | GI: nausea, vomiting, diarrhoea, abdominal pain, constipation |
| Serious/important | - Thyroid C-cell tumours (boxed warning)  <br>- Acute pancreatitis  <br>- Diabetic-retinopathy complications  <br>- Hypoglycaemia when used with insulin/sulphonylureas  <br>- Acute gall-bladder disease  <br>- Acute kidney injury (from dehydration) |
| Contra-indications | Personal/family history of medullary thyroid carcinoma (MTC) or MEN-2; hypersensitivity to semaglutide or excipients | FDA Access Data

Patients should stop Ozempic and seek care if they develop severe abdominal pain (possible pancreatitis) or neck swelling/hoarseness (possible thyroid mass).

‍